CIK 0001728117 · Non-accelerated filer<br>Smaller reporting company
Gossamer Bio, Inc.
Sign in to watch- Ticker
- GOSS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 475461709
- Phone
- (858) 684-1300
- Business address
- 3115 MERRYFIELD ROW, SUITE 120, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-05-05 | Giraudo Bryan COO/CFO | Returned to the company · Stock Option (Right to Buy) | −90,000 | 0 | ||
| 2023-05-05 | Giraudo Bryan COO/CFO | Returned to the company · Stock Option (Right to Buy) | −150,000 | 0 | ||
| 2023-05-05 | Giraudo Bryan COO/CFO | Returned to the company · Stock Option (Right to Buy) | −265,000 | 0 | ||
| 2023-05-05 | Giraudo Bryan COO/CFO | Grant or award · Stock Option (Right to Buy) | +96,667 | 96,667 | ||
| 2023-05-05 | Giraudo Bryan COO/CFO | Grant or award · Stock Option (Right to Buy) | +47,667 | 47,667 | ||
| 2023-05-05 | Giraudo Bryan COO/CFO | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2023-05-05 | Giraudo Bryan COO/CFO | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2023-05-05 | Giraudo Bryan COO/CFO | Grant or award · Stock Option (Right to Buy) | +176,667 | 176,667 | ||
| 2023-05-05 | Hasnain Faheem President & CEO | Grant or award · Stock Option (Right to Buy) | +750,000 | 750,000 | ||
| 2023-04-04 | Giraudo Bryan COO/CFO | Purchase | +55,000 | $1.02 | $56K | 125,990 |
| 2023-03-22 | Hasnain Faheem President & CEO | Purchase | +440,500 | $1.14 | $504K | 4,495,897 |
| 2023-03-21 | Hasnain Faheem President & CEO | Purchase | +269,389 | $1.20 | $322K | 4,055,397 |
| 2023-03-20 | Carter Laura Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +157,500 | 157,500 | ||
| 2023-03-20 | Peterson Caryn EVP, Regulatory Affairs | Grant or award · Stock Option (Right to Buy) | +157,500 | 157,500 | ||
| 2023-03-20 | Aranda Richard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +157,500 | 157,500 | ||
| 2023-03-20 | Christian Waage EVP, Tech Ops and Admin | Purchase | +18,500 | $1.20 | $22K | 32,388 |
| 2023-03-20 | Christian Waage EVP, Tech Ops and Admin | Grant or award · Stock Option (Right to Buy) | +157,500 | 157,500 | ||
| 2023-03-20 | Giraudo Bryan COO/CFO | Purchase | +50,000 | $0.97 | $48K | 70,990 |
| 2023-03-20 | Giraudo Bryan COO/CFO | Grant or award · Stock Option (Right to Buy) | +211,500 | 211,500 | ||
| 2023-03-20 | Hasnain Faheem President & CEO | Purchase | +168,683 | $1.03 | $174K | 3,786,008 |
Page 13 of 14 · 262 trades